Ramanan Laxminarayan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3061354/publications.pdf Version: 2024-02-01

		57758	20358
117	18,998	44	116
papers	citations	h-index	g-index
119	119	119	24230
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Gender gaps in cognitive and noncognitive skills among adolescents in India. Journal of Economic Behavior and Organization, 2022, 193, 66-97.	2.0	7
2	The overlooked pandemic of antimicrobial resistance. Lancet, The, 2022, 399, 606-607.	13.7	106
3	Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infectious Diseases, The, 2022, 22, 679-691.	9.1	32
4	All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study. Lancet Infectious Diseases, The, 2022, 22, 463-472.	9.1	28
5	Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2112410119.	7.1	18
6	Public health facility quality and child immunization outcomes in rural India: A decomposition analysis. Vaccine, 2022, 40, 2388-2398.	3.8	7
7	Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics. Lancet Infectious Diseases, The, 2022, 22, 1108-1109.	9.1	7
8	SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations. PLoS ONE, 2022, 17, e0271103.	2.5	2
9	Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infectious Diseases, The, 2021, 21, 107-115.	9.1	228
10	Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework. Clinical Infectious Diseases, 2021, 73, e1011-e1017.	5.8	64
11	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nature Communications, 2021, 12, 424.	12.8	26
12	Associations between private vaccine and antimicrobial consumption across Indian states, 2009–2017. Annals of the New York Academy of Sciences, 2021, 1494, 31-43.	3.8	7
13	Applying a One Health Approach in Global Health and Medicine: Enhancing Involvement of Medical Schools and Global Health Centers. Annals of Global Health, 2021, 87, 30.	2.0	14
14	The effect of generic market entry on antibiotic prescriptions in the United States. Nature Communications, 2021, 12, 2937.	12.8	6
15	Status, challenges and gaps in antimicrobial resistance surveillance around the world. Journal of Global Antimicrobial Resistance, 2021, 25, 222-226.	2.2	19
16	Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush. Annals of the New York Academy of Sciences, 2021, 1502, 110-120.	3.8	18
17	SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. Lancet Infectious Diseases, The, 2021, 21, 1665-1676.	9.1	38
18	Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. Lancet Microbe, The, 2021, 2, e450-e460.	7.3	36

#	Article	IF	CITATIONS
19	Antibiotic development — economic, regulatory and societal challenges. Nature Reviews Microbiology, 2020, 18, 267-274.	28.6	218
20	Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science, 2020, 370, 691-697.	12.6	377
21	Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: Evidence from the Global Enteric Multicenter Study. PLoS Neglected Tropical Diseases, 2020, 14, e0008520.	3.0	25
22	Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?. Indian Pediatrics, 2020, 57, 505-507.	0.4	4
23	Advocacy for Increased International Efforts for Antimicrobial Stewardship Actions in Low-and Middle-Income Countries on Behalf of Alliance for the Prudent Use of Antimicrobials (APUA), Under the Auspices of the International Society of Antimicrobial Chemotherapy (ISAC). Frontiers in Medicine, 2020. 7. 503.	2.6	19
24	Economic and Behavioral Influencers of Vaccination and Antimicrobial Use. Frontiers in Public Health, 2020, 8, 614113.	2.7	33
25	Global trends in antimicrobial use in aquaculture. Scientific Reports, 2020, 10, 21878.	3.3	229
26	The potential global gains in health and revenue from increased taxation of tobacco, alcohol and sugar-sweetened beverages: a modelling analysis. BMJ Global Health, 2020, 5, e002143.	4.7	30
27	The Impact of Influenza Vaccination on Antibiotic Use in the United States, 2010–2017. Open Forum Infectious Diseases, 2020, 7, ofaa223.	0.9	20
28	Childhood vaccinations and adult schooling attainment: Long-term evidence from India's Universal Immunization Programme. Social Science and Medicine, 2020, 250, 112885.	3.8	24
29	The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. Lancet Infectious Diseases, The, 2020, 20, e51-e60.	9.1	161
30	Childhood vaccines and antibiotic use in low- and middle-income countries. Nature, 2020, 581, 94-99.	27.8	85
31	India's Battle against COVID-19: Progress and Challenges. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1343-1347.	1.4	14
32	Anthropometric, cognitive, and schooling benefits of measles vaccination: Longitudinal cohort analysis in Ethiopia, India, and Vietnam. Vaccine, 2019, 37, 4336-4343.	3.8	30
33	Quantifying uncertainty about future antimicrobial resistance: Comparing structured expert judgment and statistical forecasting methods. PLoS ONE, 2019, 14, e0219190.	2.5	13
34	Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science, 2019, 365, .	12.6	594
35	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. The Lancet Global Health, 2019, 7, e861-e871.	6.3	213
36	<i>Haemophilus influenzae</i> type b vaccination and anthropometric, cognitive, and schooling outcomes among Indian children. Annals of the New York Academy of Sciences, 2019, 1449, 70-82.	3.8	18

#	Article	IF	CITATIONS
37	Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions. ACS Infectious Diseases, 2019, 5, 1265-1268.	3.8	6
38	Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Global Health, 2019, 4, e001315.	4.7	96
39	Incentivizing hospital infection control. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6221-6225.	7.1	22
40	Antibiotic resistance, stewardship, and consumption – Authors' reply. Lancet Planetary Health, The, 2019, 3, e68.	11.4	0
41	Twitter to engage, educate, and advocate for global antibiotic stewardship and antimicrobial resistance. Lancet Infectious Diseases, The, 2019, 19, 229-231.	9.1	18
42	Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?. Health Economics (United Kingdom), 2019, 28, 556-571.	1.7	14
43	Excessive use of medically important antimicrobials in food animals in Pakistan: a five-year surveillance survey. Global Health Action, 2019, 12, 1697541.	1.9	53
44	The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational Study. Clinical Infectious Diseases, 2019, 69, 563-570.	5.8	121
45	Is the efficacy of antibiotic prophylaxis for surgical procedures decreasing? Systematic review and meta-analysis of randomized control trials. Infection Control and Hospital Epidemiology, 2019, 40, 133-141.	1.8	16
46	Simulating the impact of excise taxation for disease prevention in low-income and middle-income countries: an application to South Africa. BMJ Global Health, 2018, 3, e000568.	4.7	15
47	Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016. International Journal of Infectious Diseases, 2018, 71, 20-24.	3.3	14
48	Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae. International Journal of Infectious Diseases, 2018, 68, 50-53.	3.3	53
49	Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3463-E3470.	7.1	1,907
50	Investment in child and adolescent health and development: key messages from Disease Control Priorities , 3rd Edition. Lancet, The, 2018, 391, 687-699.	13.7	156
51	Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India. BMJ Global Health, 2018, 3, e000636.	4.7	11
52	Reply to Charra et al.: Global longitudinal assessment of 2019 changes in defined daily doses. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11433-E11435.	7.1	4
53	Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS ONE, 2018, 13, e0205166.	2.5	33
54	Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planetary Health, The, 2018, 2, e398-e405.	11.4	430

#	Article	IF	CITATIONS
55	Determinants of cost of routine immunization programme in India. Vaccine, 2018, 36, 3836-3841.	3.8	8
56	Reply to Abat et al.: Improved policies necessary to ensure an effective future for antibiotics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8111-E8112.	7.1	4
57	Variation in cost and performance of routine immunisation service delivery in India. BMJ Global Health, 2018, 3, e000794.	4.7	15
58	Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. Environment International, 2018, 117, 132-138.	10.0	281
59	Surveillance of antimicrobial consumption in animal production sectors of low- and middle-income countries: Optimizing use and addressing antimicrobial resistance. PLoS Medicine, 2018, 15, e1002521.	8.4	98
60	Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. Vaccine, 2017, 35, 1087-1093.	3.8	37
61	Correction to global antibiotic consumption data. Lancet Infectious Diseases, The, 2017, 17, 476-477.	9.1	4
62	How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals?. International Journal of Infectious Diseases, 2017, 54, 77-84.	3.3	119
63	Reducing antimicrobial use in food animals. Science, 2017, 357, 1350-1352.	12.6	448
64	The quadruple burden of sepsis. Cmaj, 2017, 189, E1128-E1129.	2.0	6
65	Trends in Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014. Clinical Infectious Diseases, 2017, 65, 1921-1923.	5.8	81
66	Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India. American Journal of Infection Control, 2017, 45, 1289-1291.	2.3	25
67	Counting the lives saved by DOTS in India: a model-based approach. BMC Medicine, 2017, 15, 47.	5.5	32
68	Reduced burden of childhood diarrheal diseases through increased access to water and sanitation in India: A modeling analysis. Social Science and Medicine, 2017, 180, 181-192.	3.8	54
69	Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016. Antibiotics, 2017, 6, 19.	3.7	42
70	Use antimicrobials wisely. Nature, 2016, 537, 159-161.	27.8	47
71	Self-enforcing regional vaccination agreements. Journal of the Royal Society Interface, 2016, 13, 20150907.	3.4	16
72	Global Antibiotic Use and Resistance. Open Forum Infectious Diseases, 2016, 3, .	0.9	0

#	Article	IF	CITATIONS
73	A Global Antimicrobial Conservation Fund for Low- and Middle-Income Countries. International Journal of Infectious Diseases, 2016, 51, 70-72.	3.3	22
74	Poverty and prevalence of antimicrobial resistance in invasive isolates. International Journal of Infectious Diseases, 2016, 52, 59-61.	3.3	70
75	Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. International Journal of Infectious Diseases, 2016, 50, 75-82.	3.3	94
76	Antimicrobial resistance—a threat to neonate survival. The Lancet Global Health, 2016, 4, e676-e677.	6.3	64
77	UN High-Level Meeting on antimicrobials—what do we need?. Lancet, The, 2016, 388, 218-220.	13.7	69
78	Cost Per DALY Averted in a Surgical Unit of a Private Hospital in India. World Journal of Surgery, 2016, 40, 1034-1040.	1.6	5
79	International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet, The, 2016, 387, 296-307.	13.7	114
80	Access to effective antimicrobials: a worldwide challenge. Lancet, The, 2016, 387, 168-175.	13.7	933
81	Health and economic benefits of public financing of epilepsy treatment in India: An agentâ€based simulation model. Epilepsia, 2016, 57, 464-474.	5.1	134
82	Health and economic benefits of scaling up a home-based neonatal care package in rural India: a modelling analysis. Health Policy and Planning, 2016, 31, 634-644.	2.7	12
83	Faropenem Consumption is Increasing in India. Clinical Infectious Diseases, 2016, 62, 1050.2-1052.	5.8	24
84	Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2016, 387, 1672-1685.	13.7	586
85	Current costs & projected financial needs of India′s Universal Immunization Programme. Indian Journal of Medical Research, 2016, 143, 801.	1.0	26
86	Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis. Journal of the Royal Society Interface, 2015, 12, 20141356.	3.4	2
87	Are Physicians' Prescribing Decisions Sensitive to Drug Prices? Evidence from a Freeâ€antibiotics Program. Health Economics (United Kingdom), 2015, 24, 158-174.	1.7	13
88	Quantifying uncertainty in intervention effectiveness with structured expert judgement: an application to obstetric fistula. BMJ Open, 2015, 5, e007233-e007233.	1.9	2
89	Vaccination coverage in India: A small area estimation approach. Vaccine, 2015, 33, 1731-1738.	3.8	15
90	Economics of Antibiotic Growth Promoters in Livestock. Annual Review of Resource Economics, 2015, 7, 349-374.	3.7	31

#	Article	IF	CITATIONS
91	Influence of provider and urgent care density across different socioeconomic strata on outpatient antibiotic prescribing in the USA. Journal of Antimicrobial Chemotherapy, 2015, 70, 1580-1587.	3.0	38
92	Clobal trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5649-5654.	7.1	2,521
93	Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infectious Diseases, The, 2015, 15, 1429-1437.	9.1	270
94	The need for better evidence to evaluate the health & economic benefits of India′s Rashtriya Swasthya Bima Yojana. Indian Journal of Medical Research, 2015, 142, 383.	1.0	13
95	Incentives for Reporting Disease Outbreaks. PLoS ONE, 2014, 9, e90290.	2.5	6
96	Extended-Spectrum Â-Lactamase-Producing Enterobacteriaceae Infections in Children: A Two-Center Case-Case-Control Study of Risk Factors and Outcomes in Chicago, Illinois. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 312-319.	1.3	29
97	Extended-Spectrum β-Lactamase–Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in the United States, 1999–2011. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 320-328.	1.3	101
98	The value of tracking antibiotic consumption. Lancet Infectious Diseases, The, 2014, 14, 360-361.	9.1	10
99	Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. Lancet Infectious Diseases, The, 2014, 14, 1220-1227.	9.1	104
100	Valuing vaccines using value of statistical life measures. Vaccine, 2014, 32, 5065-5070.	3.8	24
101	Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. Vaccine, 2014, 32, A151-A161.	3.8	35
102	Antibiotic effectiveness: Balancing conservation against innovation. Science, 2014, 345, 1299-1301.	12.6	146
103	Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infectious Diseases, The, 2014, 14, 742-750.	9.1	1,719
104	Reassessing the value of vaccines. The Lancet Global Health, 2014, 2, e251-e252.	6.3	49
105	Cost-Effectiveness of Treatment and Secondary Prevention of Acute Myocardial Infarction in India: A Modeling Study. Global Heart, 2014, 9, 391.	2.3	19
106	Antibiotic resistance—the need for global solutions. Lancet Infectious Diseases, The, 2013, 13, 1057-1098.	9.1	3,184
107	Global survey of polymyxin use: A call for international guidelines. Journal of Global Antimicrobial Resistance, 2013, 1, 131-134.	2.2	42
108	Seasonality and Temporal Correlation between Community Antibiotic Use and Resistance in the United States. Clinical Infectious Diseases, 2012, 55, 687-694.	5.8	187

#	Article	IF	CITATIONS
109	Diversify or focus? Spending to combat infectious diseases when budgets are tight. Journal of Health Economics, 2012, 31, 658-675.	2.7	13
110	Using Oral Vancomycin Prescriptions as a Proxy Measure for <i>Clostridium difficile</i> Infections: A Spatial and Time Series Analysis. Infection Control and Hospital Epidemiology, 2011, 32, 723-726.	1.8	10
111	Respiratory Fluoroquinolone Use and Influenza. Infection Control and Hospital Epidemiology, 2011, 32, 706-709.	1.8	25
112	India's Vaccine Deficit: Why More Than Half Of Indian Children Are Not Fully Immunized, And What Can—And Should—Be Done. Health Affairs, 2011, 30, 1096-1103.	5.2	54
113	Synthesizing epidemiological and economic optima for control of immunizing infections. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14366-14370.	7.1	57
114	Optimal control of epidemics in metapopulations. Journal of the Royal Society Interface, 2009, 6, 1135-1144.	3.4	107
115	From The Cover: Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3153-3158.	7.1	117
116	Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infectious Diseases, The, 2005, 5, 481-493.	9.1	624
117	Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infectious Diseases, The, 2005, 5, 568-580.	9.1	221